Mei Shang1, Jessie R Chung2, Michael L Jackson3, Lisa A Jackson3, Arnold S Monto4, Emily T Martin4, Edward A Belongia5, Huong Q McLean5, Manjusha Gaglani6, Kempapura Murthy6, Richard K Zimmerman7, Mary Patricia Nowalk7, Alicia M Fry2, Brendan Flannery8. 1. Epidemic Intelligence Service, CDC, United States; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States. 2. Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States. 3. Kaiser Permanente Washington Health Research Institute, United States. 4. University of Michigan and Henry Ford Health System, United States. 5. Marshfield Clinic Research Institute, United States. 6. Baylor Scott and White Health, Texas A&M University Health Science Center College of Medicine, United States. 7. University of Pittsburgh Schools of the Health Sciences and UPMC, United States. 8. Influenza Division, National Center for Immunization and Respiratory Diseases, CDC, United States. Electronic address: bflannery@cdc.gov.
Abstract
BACKGROUND: Annual influenza vaccination has been recommended for persons with high-risk conditions since the 1960s. However, few estimates of influenza vaccine effectiveness (VE) for persons with high-risk conditions are available. METHODS: Data from the U.S. Influenza Vaccine Effectiveness Network from 2012 to 2016 were analyzed to compare VE of standard-dose inactivated vaccines against medically-attended influenza among patients aged ≥6 months with and without high-risk medical conditions. Patients with acute respiratory illness were tested for influenza by RT-PCR. Presence of high-risk conditions and vaccination status were obtained from medical records. VE by influenza virus type/subtype and age group was calculated for patients with and without high-risk conditions using the test-negative design. Interaction terms were used to test for differences in VE by high-risk conditions. RESULTS: Overall, 9643 (38%) of 25,369 patients enrolled during four influenza seasons had high-risk conditions; 2213 (23%) tested positive for influenza infection. For all ages, VE against any influenza was lower among patients with high-risk conditions (41%, 95% CI: 35-47%) than those without (48%, 95% CI: 43-52%; P-for-interaction = 0.02). For children aged <18 years, VE against any influenza was 51% (95% CI: 39-61%) and 52% (95% CI: 39-61%) among those with and without high-risk conditions, respectively (P-for-interaction = 0.54). For adults aged ≥18 years, VE against any influenza was 38% (95% CI: 30-45%) and 44% (95% CI: 38-50%) among those with and without high-risk conditions, respectively (P-for-interaction = 0.21). For both children aged <18 and adults aged ≥18 years, VEs against illness related to influenza A(H3N2), A(H1N1)pdm09, and influenza B virus infection were similar among those with and without high-risk conditions. CONCLUSIONS: Influenza vaccination provided protection against medically-attended influenza among patients with high-risk conditions, at levels approaching those observed among patients without high-risk conditions. Results from our analysis support recommendations of annual vaccination for patients with high-risk conditions. Published by Elsevier Ltd.
BACKGROUND: Annual influenza vaccination has been recommended for persons with high-risk conditions since the 1960s. However, few estimates of influenza vaccine effectiveness (VE) for persons with high-risk conditions are available. METHODS: Data from the U.S. Influenza Vaccine Effectiveness Network from 2012 to 2016 were analyzed to compare VE of standard-dose inactivated vaccines against medically-attended influenza among patients aged ≥6 months with and without high-risk medical conditions. Patients with acute respiratory illness were tested for influenza by RT-PCR. Presence of high-risk conditions and vaccination status were obtained from medical records. VE by influenza virus type/subtype and age group was calculated for patients with and without high-risk conditions using the test-negative design. Interaction terms were used to test for differences in VE by high-risk conditions. RESULTS: Overall, 9643 (38%) of 25,369 patients enrolled during four influenza seasons had high-risk conditions; 2213 (23%) tested positive for influenza infection. For all ages, VE against any influenza was lower among patients with high-risk conditions (41%, 95% CI: 35-47%) than those without (48%, 95% CI: 43-52%; P-for-interaction = 0.02). For children aged <18 years, VE against any influenza was 51% (95% CI: 39-61%) and 52% (95% CI: 39-61%) among those with and without high-risk conditions, respectively (P-for-interaction = 0.54). For adults aged ≥18 years, VE against any influenza was 38% (95% CI: 30-45%) and 44% (95% CI: 38-50%) among those with and without high-risk conditions, respectively (P-for-interaction = 0.21). For both children aged <18 and adults aged ≥18 years, VEs against illness related to influenza A(H3N2), A(H1N1)pdm09, and influenza B virus infection were similar among those with and without high-risk conditions. CONCLUSIONS:Influenza vaccination provided protection against medically-attended influenza among patients with high-risk conditions, at levels approaching those observed among patients without high-risk conditions. Results from our analysis support recommendations of annual vaccination for patients with high-risk conditions. Published by Elsevier Ltd.
Authors: Edward A Belongia; Melissa D Simpson; Jennifer P King; Maria E Sundaram; Nicholas S Kelley; Michael T Osterholm; Huong Q McLean Journal: Lancet Infect Dis Date: 2016-04-06 Impact factor: 25.071
Authors: Jacob A Udell; Rami Zawi; Deepak L Bhatt; Maryam Keshtkar-Jahromi; Fiona Gaughran; Arintaya Phrommintikul; Andrzej Ciszewski; Hossein Vakili; Elaine B Hoffman; Michael E Farkouh; Christopher P Cannon Journal: JAMA Date: 2013-10-23 Impact factor: 56.272
Authors: Michael L Jackson; Jessie R Chung; Lisa A Jackson; C Hallie Phillips; Joyce Benoit; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary P Nowalk; Alicia M Fry; Brendan Flannery Journal: N Engl J Med Date: 2017-08-10 Impact factor: 91.245
Authors: Richard K Zimmerman; Mary Patricia Nowalk; Jessie Chung; Michael L Jackson; Lisa A Jackson; Joshua G Petrie; Arnold S Monto; Huong Q McLean; Edward A Belongia; Manjusha Gaglani; Kempapura Murthy; Alicia M Fry; Brendan Flannery Journal: Clin Infect Dis Date: 2016-10-04 Impact factor: 20.999
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Sonja J Olsen; Joseph S Bresee; Karen R Broder; Ruth A Karron Journal: MMWR Morb Mortal Wkly Rep Date: 2015-08-07 Impact factor: 17.586
Authors: Fumi Sato-Kaneko; Shiyin Yao; Fitzgerald S Lao; Jonathan Shpigelman; Karen Messer; Minya Pu; Nikunj M Shukla; Howard B Cottam; Michael Chan; Paul J Chu; David Burkhart; Roman Schoener; Takaji Matsutani; Dennis A Carson; Maripat Corr; Tomoko Hayashi Journal: Front Immunol Date: 2020-06-19 Impact factor: 7.561
Authors: Huong Q McLean; Kayla E Hanson; Allison D Foster; Scott C Olson; Sarah K Kemble; Edward A Belongia Journal: Influenza Other Respir Viruses Date: 2020-01-14 Impact factor: 4.380